Biotech Briefings is a publication of Gibson Dunn’s Life Sciences Group. This is a forum to share with clients and friends our insights, updates and analysis on the latest developments and trends across the life sciences industry. Our team of experienced attorneys, with deep knowledge in healthcare, biotechnology, pharmaceuticals, and medical devices, provides expert commentary on key regulatory changes, legal trends, and market innovations that impact companies and stakeholders in this rapidly evolving field. The views expressed here should not be construed as being the firm’s policies or suggested best practices, or as substitute for legal advice that addresses specific facts and circumstances.
Gibson Dunn is committed to providing the highest quality legal services to our clients in a personal, responsive manner. The firm has more than 2,000 lawyers in 21 offices located in major cities throughout the United States, Europe, South America, the Middle East and Asia.
Our Life Sciences Group is consistently recognized as one of the leading practices in the United States. Chambers USA, LMG Life Sciences and US Legal 500 have named our group among the leading life sciences practices in the country. Our Life Sciences group was winner of the Life Sciences Group of the Year by Law360 from 2020 through 2023.
Our lawyers deliver unparalleled expertise and strategic guidance to life sciences companies at any stage. We represent clients across the biotechnology, pharmaceutical, diagnostics and medical device industries, with our clients ranging from global pharmaceutical giants to emerging biotechnology companies. Our life sciences lawyers represent companies in the full spectrum of legal services, including public and private capital markets, litigation (IP and commercial disputes), M&A, licensing and strategic transactions, white collar and regulatory compliance, competition advisory and royalty-based financing.
For more information, please visit Gibson Dunn’s Life Sciences Group page.